Valuation UCB

Stocks

Market Closed - Euronext Bruxelles 18:55:00 16/10/2026 +03			5-day change	1st Jan Change
204.60 ^EUR	-0.68%		+0.54%	-14.25%

10-16	UCB Announces U.S. FDA Approval for ZILBRYSQ Autoinjector Self-Administration for Adults Living with Generalized Myasthenia Gravis	CI
10-16	UCB Gets US FDA Nod for Autoinjector Version of Myasthenia Gravis Drug	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	18,947	13,973	14,969	36,464	45,333	39,010	-	-
Change	-	-26.25%	7.12%	143.6%	24.32%	-13.95%	-	-
Enterprise Value (EV) ¹	19,807	15,973	17,146	37,918	45,326	39,422	37,315	34,814
Change	-	-19.36%	7.34%	121.15%	19.54%	-13.03%	-5.35%	-6.7%
P/E	17.9x	33.4x	44.8x	34.3x	29.1x	20.5x	17x	14.1x
PBR	2.32x	1.58x	1.67x	3.64x	4.18x	3.24x	2.83x	2.35x
PEG	-	-0.6x	-2.2x	0x	0.6x	0.9x	0.8x	0.7x
Capitalization / Revenue	3.28x	2.53x	2.85x	5.93x	5.86x	4.51x	4.06x	3.65x
EV / Revenue	3.43x	2.9x	3.26x	6.16x	5.86x	4.55x	3.88x	3.26x
EV / EBITDA	12.1x	12.7x	12.7x	25.7x	17.2x	12.9x	10.3x	8.21x
EV / EBIT	15x	23.7x	26.1x	45.4x	22.6x	16x	12.5x	9.59x
EV / FCF	15.6x	18.4x	38.5x	41.2x	24.6x	20.6x	14.3x	11.3x
FCF Yield	6.42%	5.43%	2.6%	2.43%	4.06%	4.84%	7%	8.85%
Dividend per Share ²	1.3	1.33	1.36	1.39	1.45	1.457	1.502	1.534
Rate of return	1.3%	1.81%	1.72%	0.72%	0.61%	0.71%	0.73%	0.75%
EPS ²	5.6	2.2	1.76	5.61	8.2	9.998	12.01	14.48
Distribution rate	23.2%	60.5%	77.3%	24.8%	17.7%	14.6%	12.5%	10.6%
Net sales ¹	5,777	5,517	5,252	6,152	7,741	8,659	9,607	10,682
EBITDA ¹	1,641	1,260	1,349	1,476	2,636	3,053	3,621	4,240
EBIT ¹	1,318	675	657	836	2,009	2,463	2,979	3,630
Net income ¹	1,058	418	343	1,065	1,558	1,928	2,297	2,758
Net Debt ¹	860	2,000	2,177	1,454	-7	412.7	-1,695	-4,196
Reference price ²	100.35	73.56	78.90	192.20	238.60	204.60	204.60	204.60
Nbr of stocks (in thousands)	188,812	189,959	189,721	189,720	189,996	190,663	-	-
Announcement Date	2/24/22 A	2/22/23 A	2/28/24 A	2/27/25 A	2/24/26 A	-	-	-

¹EUR in Million²EUR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
UCB	20.46x	4.55x	12.91x	0.71%	43.89B
ELI LILLY AND COMPANY	35.96x	12.96x	27.14x	0.55%	1,120B
JOHNSON & JOHNSON	37.4x	6.3x	17.74x	2.09%	616B
ABBVIE INC.	36.43x	8.36x	17.24x	2.43%	504B
ROCHE HOLDING AG	20.46x	4.99x	12.38x	2.64%	367B
MERCK & CO., INC.	106.52x	5.95x	25.12x	2.33%	360B
NOVARTIS AG	21.18x	5.54x	13.63x	2.88%	288B
ASTRAZENECA PLC	21.7x	4.38x	12.55x	2.01%	258B
AMGEN INC.	27.46x	7.06x	12.64x	2.33%	234B
GILEAD SCIENCES, INC.	-45.63x	6.99x	27.07x	2.11%	194B
Average	28.19x	6.71x	17.84x	2.01%	398.48B
Weighted average by Cap.	34.57x	8.16x	19.96x	1.82%